For research use only. Not for therapeutic Use.
NVP-BVU972 is an selective and potent Met inhibitor, with an IC50 of 14 nM. NVP-BVU972 also exhibits good anti-proliferative activity against Met with drug-resistant mutations and inhibits phosphorylation. NVP-BVU972 can be used in study of cancer[1].
NVP-BVU972 (600 nM-9.6 µM; 72 h) shows good antiproliferative activity to BaF3 cells with MET mutations[1].
NVP-BVU972 (0-10 µM; 2 h) reduces TPR-MET phosphorylation in a dose-dependent manner in BaF3 TPR-MET cells[1].
| Catalog Number | I000662 |
| CAS Number | 1185763-69-2 |
| Synonyms | 6-[[6-(1-methylpyrazol-4-yl)imidazo[1,2-b]pyridazin-3-yl]methyl]quinoline |
| Molecular Formula | C20H16N6 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H16N6/c1-25-13-16(11-23-25)19-6-7-20-22-12-17(26(20)24-19)10-14-4-5-18-15(9-14)3-2-8-21-18/h2-9,11-13H,10H2,1H3 |
| InChIKey | RNCNPRCUHHDYPC-UHFFFAOYSA-N |
| SMILES | CN1C=C(C=N1)C2=NN3C(=NC=C3CC4=CC5=C(C=C4)N=CC=C5)C=C2 |
| Reference | [1]. Tiedt, Ralph, et al. A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients. Cancer Research (2011), 71(15), 5255-5264. |
